DRG Market Assessment reports

Small cell lung cancer (SCLC) accounts for approximately 15% of all lung cancer cases and is particularly aggressive with a 5 year survival rate of just 5-10%. Historically, drug development in…

The malignant melanoma treatment landscape is dynamic and continues to undergo significant changes. Since 2011, three immune checkpoint inhibitors and four BRAF- or MEK-targeted agents have gained…

Ushering in a New Era of Cancer Immunotherapies in NSCLC, Malignant Melanoma, Renal Cell Carcinoma, and SCCHN The field of cancer immunotherapy has witnessed considerable advances over the past few…

Over the last 15 years, we have witnessed a notable shift in oncology drug development activity. Since the U.S. approval of Roche/Genentech’s Herceptin (trastuzumab) in 1998, pharmaceutical…

Immunotherapy is one of the most exciting areas of oncology drug development. Numerous manufacturers and investors are entering the field and are rapidly expanding and diversifying their portfolios…

A Survey of Medical Oncologists and Managed Care Organization Pharmacy and Medical Directors The hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC) markets differ with respect to…

Cancer immunotherapy is one of the most exciting fields of research in oncology. Successful drug development in this space offers a highly lucrative opportunity for drug developers. Most excitement…

Renal cell carcinoma (RCC) is a disease characterized by significant unmet need and, thus, opportunity. Its incidence is increasing in the major pharmaceutical markets, and many patients with early…